Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide in IBS-C (LIN-MD-31)
NCT00948818Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Jul 2009
- Primary completion
- Jul 2010
- Modality
- Peptides
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Linaclotide with Placebo (2 arms). Primary endpoints: Abdominal Pain and Complete Spontaneous Bowel Movement Responder, 9 Out of 12 Weeks, Complete Spontaneous Bowel Movement 3+1 Responder, 9 Out of 12 Weeks and 2 more. Started Jul 2009; status: completed.
02
Drugs
linaclotide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT00948818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00948818.